louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04966416: Calcinosis Reduction by Pyrophosphate in SSC
Official title: The Effect of Orally Administered Pyrophosphate on Calcinosis Formation in Systematic Sclerosis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Systemic Sclerosis
Scleroderma
Keywords: calcinosis
pyrophosphate
Lead sponsor: Szeged University
Sponsor class: OTHER
Collaborators: name: Research Centre for Natural Sciences
name: University of Debrecen Dept. of Rheumatology
First posted: 2021-07-19
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Calcinosis, i.e. crystal-like nodules are troublesome complication of systemic sclerosis, an autoimmune disease. Pyrophosphate inhibits its formation is laborytory. We would like to test if orally administered pyrophosphate prevents calcinosis formation.

Detailed description: Calcinosis, the formation of hydroxyapatite subcutaneous nodules, often complicates systemic sclerosis. There is no standard treatment for it. Based upon our preclinical experienc, we would like to test it orally administered pyrophosphate inhibits calciosis.

Eligibility criteria: Inclusion Criteria:

* to meet ACR/ EULAR classification criteria

Exclusion Criteria:

* severe upper minfestation of SSC
* hypo- or hyperthyreoidism
* QT prolongation on ECG

Primary outcomes:
measure: Change in the size of calcinosis nodues.
timeFrame: 52 weeks+ 16 weeks
Secondary outcomes:
measure: Change of the severity of sympthoms caused by calcinosis
timeFrame: 52 weeks+ 16 weeks
measure: Change of the activity of calcinosis
timeFrame: 52 weeks+ 16 weeks
measure: Change of the size of calcinosis by ultrasound
timeFrame: 52 weeks+ 16 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Szeged University
name: László Kovács, MD, Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Enzymology, Research Centre for Natural Sciences
name: András Váradi, PhD, DSc
role: STUDY_DIRECTOR
References:
citation: Hsu VM, Kozak E, Li Q, Bocskai M, Schlesinger N, Rosenthal A, McClure ST, Kovacs L, Balint L, Szamosi S, Szucs G, Carns M, Aren K, Goldberg I, Varadi A, Varga J. Inorganic pyrophosphate is reduced in patients with systemic sclerosis. Rheumatology (Oxford). 2022 Mar 2;61(3):1158-1165. doi: 10.1093/rheumatology/keab508.
citation: Dedinszki D, Szeri F, Kozak E, Pomozi V, Tokesi N, Mezei TR, Merczel K, Letavernier E, Tang E, Le Saux O, Aranyi T, van de Wetering K, Varadi A. Oral administration of pyrophosphate inhibits connective tissue calcification. EMBO Mol Med. 2017 Nov;9(11):1463-1470. doi: 10.15252/emmm.201707532.
Clinical trial NCT00715416: PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents
Official title: Balloon Angioplasty vs. Primary Stenting of Femoropopliteal Arteries Using Self-Expandable Nitinol Stents - a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Peripheral Vascular Diseases
Intermittent Claudication
Angioplasty
Keywords: peripheral vascular diseases
Intermittent Claudication
Angioplasty
Lead sponsor: Vienna General Hospital
Sponsor class: OTHER
First posted: 2008-07-15
Enrollment: 76
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators evaluated whether primary implantation of a self-expanding nitinol stent yielded anatomical and clinical benefits superior to those afforded by percutaneous transluminal angioplasty with optional secondary stenting.


Eligibility criteria: Inclusion Criteria:

* symptomatic peripheral artery disease with severe intermittent claudication (Fontaine stage IIb)
* critical limb ischemia in patients with stenosis or occlusions originating in the SFA
* up to 25 cm length of stenosis/occlusion

Exclusion Criteria:

* previous bypass surgery at the site of treatment
* history of intolerance of anti-platelet therapy
* adverse reaction to heparin
* bleeding diathesis
* creatinine \>2.5 mg/dL
* active bacterial infection
* allergy to contrast media
* previous stent placement at or immediately adjacent to the target lesion

Primary outcomes:
measure: occurrence of a >50% restenosis at the treated segment at 6 months postintervention as determined by CTA (in-segment restenosis).
timeFrame: 3, 6, 12 months
Secondary outcomes:
measure: ultrasound patency, clinical patency, target vessel and target lesion revascularization, cardiovascular events, quality of life at 3, 6 and 12 months after the procedure
timeFrame: 3, 6, 12 months
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: University Hospital of Vienna
Study officials:
affiliation: General Hospital of Vienna, Department of Angiology
name: Martin Schilliger, Prof
role: PRINCIPAL_INVESTIGATOR
affiliation: General Hospital of Vienna
name: Martin Schillinger, Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006 May 4;354(18):1879-88. doi: 10.1056/NEJMoa051303.
Clinical trial NCT00207116: An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Official title: An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Keywords: Metastatic Non Small Cell Lung Cancer
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2005-09-21
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer


Eligibility criteria: Inclusion Criteria:

* Measurable disease tumor available for biopsies
* Life expectancy of at least 3 months

Exclusion Criteria:

* Known or documented brain metastases prior to Cetuximab therapy

Primary outcomes:
measure: Prediction of response to Erbitux with non small cell lung cancer
Secondary outcomes:
measure: Radiographic Response
Other outcomes:
Locations:
city: Newark
country: United States
facility: Local Institution
state: Delaware
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT03956316: Short-Term Outcomes of Total Shoulder Arthroplasty Using the Titan Modular Total Shoulder System
Official title: Short-Term Outcomes of Total Shoulder Arthroplasty Using the Titan Modular Total Shoulder System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Shoulder Disease
Lead sponsor: OrthoIndy
Sponsor class: OTHER
Collaborators: name: Integra LifeSciences Corporation
First posted: 2019-05-20
Enrollment: 25
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 39 subjects received total shoulder arthroplasty using the Titan Modular Total Shoulder System. 25 subjects agreed to participate in the study.

Brief summary: The goals of total, reverse total and hemi shoulder arthroplasty are the same, to alleviate the patient's pain and obtain a full functional recovery. This outcome depends on the surgeon's ability to reproduce normal glenohumeral anatomy including bone morphology, capsular tension and rotator cuff function. Shoulder arthroplasty has become a safe and effective treatment for various diseases of the shoulder. This study goal is to document and report the short-term functional, radiographic, and quality of life outcomes of total shoulder arthroplasty (TSA) using the titan modular shoulder system.


Eligibility criteria: Inclusion Criteria:

* Total shoulder arthroplasty using the Titan Modular Total Shoulder System

Exclusion Criteria:

* Declining to participate

Primary outcomes:
measure: ASES
timeFrame: two year post op
measure: EQ-5D-5L
timeFrame: two year post op
measure: PENN
timeFrame: two year post op
measure: SANE
timeFrame: two year post op
measure: CS
timeFrame: two year post op
measure: WOOS
timeFrame: two year post op
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01600716: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Urinary Incontinence
Multiple Sclerosis
Neurogenic Bladder
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2012-05-17
Enrollment: 144
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.


Eligibility criteria: Inclusion Criteria:

* At least 3 episodes of urinary incontinence over a 3-day period
* History of Multiple Sclerosis (MS)
* Urinary incontinence not adequately controlled by anticholinergic medication

Exclusion Criteria:

* Current use of intermittent catheter or indwelling catheter to manage urinary incontinence
* Previous or current botulinum toxin therapy of any serotype for any urological condition
* Previous or current botulinum toxin therapy of any serotype for any non-urological condition within the last 12 weeks
* Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, or Amyotrophic Lateral Sclerosis

Primary outcomes:
measure: Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes
timeFrame: Baseline, Week 6
Secondary outcomes:
measure: Change From Baseline in Maximum Cystometric Capacity (MCC)
timeFrame: Baseline, Week 6
measure: Change From Baseline in Maximum Detrusor Pressure During the First Involuntary Detrusor Contraction (IDC)
timeFrame: Baseline, Week 6
measure: Change From Baseline in Incontinence Quality of Life Instrument (I-QOL) Total Summary Score
timeFrame: Baseline, Week 6
Other outcomes:
measure: Duration of Treatment Effect Through Week 52
timeFrame: Up to 52 Weeks
Locations:
city: Mountlake Terrace
country: United States
state: Washington
city: Liege
country: Belgium
city: Victoria
country: Canada
state: British Columbia
city: Kitchener
country: Canada
state: Ontario
city: Olomouc
country: Czechia
city: Garches
country: France
city: Marseille
country: France
city: Warsaw
country: Poland
city: Porto
country: Portugal
city: St. Petersburg
country: Russian Federation
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Tullman M, Chartier-Kastler E, Kohan A, Keppenne V, Brucker BM, Egerdie B, Mandle M, Nicandro JP, Jenkins B, Denys P. Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS. Neurology. 2018 Aug 14;91(7):e657-e665. doi: 10.1212/WNL.0000000000005991. Epub 2018 Jul 20.
Clinical trial NCT03137316: Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy
Official title: Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Secondary Hyperparathyroidism
Diabetic Nephropathies
Lead sponsor: Benha University
Sponsor class: OTHER
Collaborators: name: New Jeddah Clinic Hospital
First posted: 2017-05-02
Enrollment: 437
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 437 diabetic patients were enrolled in this study from 864 diabetic patients who attended diabetes and nephrology outpatient clinics in our tertiary care hospital in Jeddah from Jan 2014 to Feb 2017.

Brief summary: The aim of this study is to evaluate the prevalence of secondary hyperparathyroidism among patients with diabetic nephropathy.


Eligibility criteria: Inclusion Criteria:

* \[1\] Age was above 18 years, \[2\] Patient had diabetic nephropathy which was diagnosed based on the presence of urinary albumin/creatinine ratio (uACR) ≥ 30 mg/gm ± 24 hours' urinary protein measurement ≥ 300 mg/day

Exclusion Criteria:

* \[1\] patients were already receiving cinacalcet and/or \[2\] patients had undergone neck surgery for parathyroidectomy.

Primary outcomes:
measure: intact parathyroid level
timeFrame: within 1 hour from attending in the clinic
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04767516: Multicenter Subcutaneous ICD Registry
Official title: Multicenter Registry of Subcutaneous ICD Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: ICD
ICD Malfunction
Lead sponsor: Universitätsklinikum Köln
Sponsor class: OTHER
Collaborators: name: Uniklinik Ulm
name: St.Barts Hospital, London
name: VCU Hospital, Richmond
name: University Hospital, Bordeaux
name: University Hospital Southampton NHS Foundation Trust
name: La Fe Hospital Valencia
name: Med.Hochschule Hannover
name: EVKLN Duisburg
name: Veterans Affairs Hospital San Juan
name: Colorado Childrens Hospital
name: Stanford Healthcare
name: Uniklinik Giessen
First posted: 2021-02-23
Enrollment: 1300
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with an S-ICD

Brief summary: This multicenter registry aims to collect data regarding S-ICD longevity, and battery and lead failure rates. Only clinically collected data is gathered in this registry.


Eligibility criteria: Inclusion Criteria:

* S/P S-ICD Implantation

Exclusion Criteria:

* n/a

Primary outcomes:
measure: Generator Explantation
timeFrame: from baseline to incidence of explantation through study completion, an average of 5 year
measure: Lead Failure
timeFrame: from baseline to incidence of lead failure,through study completion, an average of 5 year
Secondary outcomes:
measure: Battery Longevity
timeFrame: from baseline to incidence of battery depletion through study completion, an average of 5 year
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: University Hospital Cologne
state: NRW
Study officials:
References:
citation: Luker J, Strik M, Andrade JG, Raymond-Paquin A, Elrefai MH, Roberts PR, Perez OC, Kron J, Koneru J, Franqui-Rivera H, Sultan A, Ernst A, Schmitt J, Pott A, Veltmann C, Srinivasan NT, Collinson J, van Stipdonk AMW, Linz D, Fluschnik N, Tonnis T, Haeberlin A, Ploux S, Steven D. Incidence of premature battery depletion in subcutaneous cardioverter-defibrillator patients: insights from a multicenter registry. J Interv Card Electrophysiol. 2023 Jan 18. doi: 10.1007/s10840-023-01468-1. Online ahead of print.
Clinical trial NCT06072716: The Anti-fungal Effect of Miconazol Versus Miconazol-Loaded Chitosan Nanoparticles
Official title: The Anti-fungal Effect of Miconazol and Miconazol-Loaded Chitosan Nanoparticles in Diabetic Patients With Oral Candidiasis-Randomized Control Clinical Trial and Microbiological Analysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Oral Thrush
Keywords: diabetic patients or oral candidiasis or oral thrush
Lead sponsor: MTI University
Sponsor class: OTHER
First posted: 2023-10-10
Enrollment: 80
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 1:1 parallel arms
Primary purpose: TREATMENT

Brief summary: Objective: this study aimed to evaluate the therapeutic effects of topical application of miconazole and miconazole-loaded chitosan nanoparticles in treatment diabetic patients with oral candidiasis.

Detailed description: Abstract:

Objective: this study aimed to evaluate the therapeutic effects of topical application of miconazole and miconazole-loaded chitosan nanoparticles in treatment diabetic patients with oral candidiasis.

Subjective and methods:

In this randomized controlled clinical trial,. A total of 80 diabetic patients presenting with symptomatic oral candidiasis were randomly assigned into two treatment groups: miconazole and miconazole-loaded chitosan nanoparticles. The patients were treated for a duration 28days , and clinical assessments were conducted at baseline, 7, 14, 21 and 28 days.

Microbiological analysis was performed to determine the Candida species and assess their susceptibility to the antifungal agents. Clinical parameters, including signs and symptoms of oral candidiasis, were also evaluated.

.

Eligibility criteria: Inclusion Criteria:

1. uncontrolled diabetes patients with oral candidiasis and their uncontrolled diabetes were confirmed by doing glycated hemoglobin test and their range is \>7.0%,
2. age ranged from 30-65 years
3. patients were willing to participate in this study

Exclusion Criteria:

1. immunocompromised and patients with systemic diseases that can cause muscle weakness as Parkinson's disease, or others that can limit their cognitive functioning such as dementia
2. pregnant
3. nursing women
4. smokers
5. alcoholic patients were also excluded from the study.
6. should not have a history of use of any drugs that can cause hyposalivation or broad spectrum antibiotics, within the last month.

Primary outcomes:
measure: clinical assessment of erythematous/psuedomembranous oral candidiasis resolution
timeFrame: 28 days
Secondary outcomes:
measure: microbiological count of candida
timeFrame: 28 days
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: radwa Elsherif
Study officials:
affiliation: MUST
name: radwa ELsherif, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02944916: Pilot Study Evaluating the Use of a New Device for Transanal Irrigation in Patient With Bowel Disorders
Official title: Pilot Study Evaluating the Use of a New Device for Transanal Irrigation in Patient With Bowel Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Therapeutic Irrigation
Lead sponsor: BBraun Medical SAS
Sponsor class: INDUSTRY
First posted: 2016-10-26
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study descripted of efficacy of IryPump®R Set in term of success of the procedure at each irrigation


Eligibility criteria: Inclusion Criteria:

1. Patient is at least 18 years old,
2. Patient having signed an informed consent
3. Patient having neurologic or non neurologic bowel disorders, being initiated to TAI and practicing TAI with Peristeen® for the management of her/his bowel disorders, for at least 6 weeks, with satisfying results.
4. Patient practicing TAI on the basis of 1 procedure/ week as a minimum or more frequently
5. Patient capable to perform the procedure of transanal irrigation himself or with the help of a caregiver
6. Patient having a mental capacity to participate to the study (i.e. to understand the study and to answer to the questions)
7. Patient agrees to test IryPump® Set R for a time corresponding to 5 consecutive irrigations and a maximum of 4 weeks.
8. Patient covered by social security

Exclusion Criteria:

1. Patient with bowel obstruction
2. Patient already participating in another clinical study or who have previously participated in this investigation,
3. Pregnant or breast-feeding woman

Primary outcomes:
measure: Success of the trans anal irrigation (TAI) procedure
timeFrame: Duration of the study per patient will correspond to the realisation of 5 consecutive TAI in a maximum of 41 days of follow up
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Henry Gabrielle Hospital- St Genis Laval- France
name: Kathleen Charvier
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04709016: Drug Use During Sex and Its Impact on Taking PrEP (Pre-Exposure Prophylaxis) : CONSUME
Official title: The Use of Chemsex (Drug Use in a Sexual Context) Among MSM (Men Who Have Sex With Men) and Transgender People in France, Whether or Not Taking PrEP, and Its Impact on PrEP Adherence
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Drug Dependence
Keywords: Chemsex
PrEP
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2021-01-14
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study concerns subjects of male or transgender sex, of MSM or bi-sexual sexual orientation, consulting in sexual health centers.

Brief summary: This is a cross-sectional, single-center observational study conducted from October 2020 to March 2021 in Ile de France at the infectious disease of CHU Bichat (PrEP and CeGIDD(Free Center for Information, Screening and Diagnosis of Infections by Human Immunodeficiency Viruses, Viral Hepatitis and Sexually Transmitted Infections) consultation). It concerns adult subjects of male or transgender sex, of MSM (men having sex with men) or bi-sexual orientation. The data are collected by self-questionnaire evaluating the consumption of Chemsex (drug use in a sexual context) over the last 12 months, the existence or not of addiction treatment, the history of STIs (sexually transmitted infections) and adherence to PrEP (for subjects taking PrEP) during the last sexual intercourse (ANRS questionnaire, used in the PREVENIR study).


Eligibility criteria: Inclusion Criteria:

* age\> 18
* male or transgender
* MSM or bi-sexual orientation
* adult consultant at Bichat Hospital (CeGIDD or PrEP consultation)
* adult with a Smartphone (online self-questionnaire)

Exclusion Criteria:

* For the group "taking PrEP": adult taking PrEP for less than 3 months
* Refusal of participation

Primary outcomes:
measure: compare in an MSM and transgender population, the use of Chemsex depending on whether or not PrEP is taken
timeFrame: inclusion
Secondary outcomes:
measure: Reported adherence to PrEP
timeFrame: inclusion
measure: The existence or not of psychological comorbidity and the existence of addictological care
timeFrame: inclusion
measure: The number of sexually transmitted infections at inclusion
timeFrame: inclusion
Other outcomes:
Locations:
city: Paris
country: France
facility: SMIT - Hôpital Bichat
Study officials:
References: